HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 15 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
NPY5R
neuropeptide Y receptor Y5
Chromosome 4 · 4q32.2
NCBI Gene: 4889Ensembl: ENSG00000164129.13HGNC: HGNC:7958UniProt: Q15761
41PubMed Papers
20Diseases
2Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Receptor
CLINICAL
Clinical Trials
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
outflow tract morphogenesiscardiac left ventricle morphogenesisneuropeptide signaling pathwaypancreatic polypeptide receptor activityobesityneurodegenerative diseasemathematical abilityacquired thrombocytopenia
✦AI Summary

NPY5R is a G protein-coupled receptor that mediates neuropeptide Y (NPY) and peptide YY signaling through inhibition of adenylate cyclase 1. The receptor plays pleiotropic roles across multiple physiological systems. In metabolic regulation, NPY5R expression in adipose tissue is downregulated by leptin and involved in neuroendocrine control of adipocyte metabolism; reduced NPY5R levels are observed in obesity and insulin resistance 2. NPY5R activation in hepatocytes promotes apolipoprotein A1 synthesis and secretion via ERK1/2 and PKA signaling pathways, suggesting cardioprotective potential through enhanced cholesterol reverse transport 1. Beyond metabolism, NPY5R is essential for extrapulmonary metastasis in Ewing sarcoma through RhoA-dependent cell motility 3, and its inhibition reduces hypoxia-enhanced breast cancer migration and proliferation 4. In normal development, NPY5R is implicated in hippocampal learning and memory; hemizygosity for NPY5R has been associated with autism spectrum disorder in a chromosome 4 deletion case 5. Genetic variation in NPY5R associates with left ventricular hypertrophy phenotypes in hypertensive populations 6. Dysregulated NPY5R expression appears linked to cervical squamous cell carcinoma 7. These findings establish NPY5R as a therapeutic target across obesity, cardiovascular disease, and cancer pathologies.

Sources cited
1
NPY5R expression in adipose tissue is selectively reduced by leptin; downregulated in obesity and insulin resistance; involved in neuroendocrine regulation of adipocyte metabolism
PMID: 39293775
2
NPY5R activation promotes hepatic apolipoprotein A1 synthesis and secretion through ERK1/2 and PKA signaling pathways; NPY5R is a therapeutic target for cardiovascular disease
PMID: 35660638
3
NPY5R is essential for Ewing sarcoma extrapulmonary metastasis; mediates NPY-induced cell motility through RhoA activation; autocrine NPY/Y5R loop maintains basal cell motility
PMID: 40676141
4
NPY5R antagonism reduces hypoxic breast cancer migration, proliferation, and MAPK signaling; NPY5R protein levels correlate with advanced cancer
PMID: 37264315
5
Hemizygosity for NPY5R associated with autism spectrum disorder in chromosome 4q deletion; NPY5R plays role in hippocampal learning and memory
PMID: 15090072
6
NPY5R genetic variation associates with left ventricular hypertrophy phenotypes in hypertensive populations
PMID: 19593212
7
NPY5R is differentially downregulated in cervical squamous cell carcinoma compared to adenocarcinoma and normal tissues
PMID: 36184073
8
NPY5R identified as uremic toxin receptor involved in vascular inflammation associated with hyperlipidemia and chronic kidney disease
PMID: 40505347
Disease Associationsⓘ20
obesityOpen Targets
0.37Weak
neurodegenerative diseaseOpen Targets
0.20Weak
mathematical abilityOpen Targets
0.12Weak
acquired thrombocytopeniaOpen Targets
0.12Weak
hemiplegiaOpen Targets
0.11Weak
COVID-19Open Targets
0.11Weak
asthmaOpen Targets
0.11Weak
connective tissue diseaseOpen Targets
0.11Weak
Sjogren syndromeOpen Targets
0.11Weak
adverse effectOpen Targets
0.10Weak
response to stimulusOpen Targets
0.10Suggestive
hyperpituitarismOpen Targets
0.09Suggestive
breast cancerOpen Targets
0.08Suggestive
schizophreniaOpen Targets
0.07Suggestive
obesity due to melanocortin 4 receptor deficiencyOpen Targets
0.07Suggestive
MODYOpen Targets
0.07Suggestive
inherited obesityOpen Targets
0.06Suggestive
obesity and hypopigmentationOpen Targets
0.06Suggestive
hyperinsulinism due to INSR deficiencyOpen Targets
0.06Suggestive
severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiencyOpen Targets
0.05Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets2
MK-0557Phase III
Neuropeptide Y receptor type 5 antagonist
obesity
VELNEPERITPhase II
Neuropeptide Y receptor type 5 antagonist
obesity
Related Genes
PPYProtein interaction97%POMCProtein interaction85%PYYProtein interaction84%SSTR1Protein interaction76%SSTR5Protein interaction75%MCHR1Protein interaction75%
Tissue Expression6 tissues
Heart
100%
Liver
76%
Brain
50%
Ovary
9%
Lung
9%
Bone Marrow
8%
Gene Interaction Network
Click a node to explore
NPY5RPPYPOMCPYYSSTR1SSTR5MCHR1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q15761
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
1.18LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.82 [0.58–1.18]
RankingsWhere NPY5R stands among ~20K protein-coding genes
  • #10,044of 20,598
    Most Researched41
  • #12,376of 17,882
    Most Constrained (LOEUF)1.18
Genes detectedNPY5R
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
PMID: 23427353
1.00
2
The adipose tissue melanocortin 3 receptor is targeted by ghrelin and leptin and may be a therapeutic target in obesity.
PMID: 39293775
Mol Cell Endocrinol · 2024
0.90
3
Uremic toxin receptor NR1H3 contributes to hyperlipidemia- and chronic kidney disease-accelerated vascular inflammation, which is partially suppressed by novel YBX2 anti-ROS pathway.
PMID: 40505347
Redox Biol · 2025
0.80
4
Neuropeptide Y promotes hepatic apolipoprotein A1 synthesis and secretion through neuropeptide Y Y5 receptor.
PMID: 35660638
Peptides · 2022
0.70
5
A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R.
PMID: 15090072
BMC Med Genet · 2004
0.60